PVI
ROIV icon

Pura Vida Investments’s Roivant Sciences ROIV Stock Holding History

Pura Vida Investments’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-104,413
Closed -$1.05M – 279
2021
Q4 		$1.05M Buy
+104,413
New +$869K 0.04% 176

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pura Vida Investments's ROIV Position: Q1 2022 in Review

Pura Vida Investments sold out of Roivant Sciences (ROIV) in Q1 2022, closing a stake of 104,413 shares — an estimated $1.05M sold.

Pura Vida Investments first reported a position in ROIV in Q4 2021 and held it in 1 quarter. The position peaked at $1.05M in Q4 2021. 52 funds tracked by Wall St. Rank hold ROIV as of Q1 2022.

  • Pura Vida Investments reported no remaining Roivant Sciences position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 104,413 Roivant Sciences shares in Q1 2022, an estimated $1.05M.
  • Pura Vida Investments first reported a position in Roivant Sciences in Q4 2021 and held it in 1 quarter.
  • Pura Vida Investments's Roivant Sciences position peaked at $1.05M in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.